{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-036937","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.825997+00:00","generated_at":"2026-05-15T08:15:04.175434+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cadrenal Therapeutics reports Q4 net loss of $3.0M, cash $4.0M; CAD-1005 FDA EOP2 meeting completed","bullets":["Q4 2025 net loss $3.0M vs $4.2M YoY; R&D expenses $0.7M vs $1.5M; G&A $2.4M vs $2.7M.","Cash and equivalents $4.0M at Dec 31, 2025; evaluating financing and strategic alternatives to support clinical development.","Completed End-of-Phase 2 FDA meeting on March 26, 2026 for CAD-1005; Phase 3 pivotal trial protocol incorporation underway.","Phase 2 HIT study showed >25% absolute reduction in thrombotic events with CAD-1005 vs placebo on standard anticoagulation.","CAD-1005 has Orphan Drug and Fast Track designations from FDA; orphan status from EMA."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-036937","json":"https://secwatch.observer/filing/0001213900-26-036937.json","markdown":"https://secwatch.observer/filing/0001213900-26-036937.md","text":"https://secwatch.observer/filing/0001213900-26-036937.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000121390026036937/0001213900-26-036937-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000121390026036937/ea0284258-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:15:04.175434+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7c8ccb0c2bf0a672a0f4d352acd29d085ee68809","claim":"Cadrenal Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income $3.0 million for the quarter ending December 31, 2025.","evidence_excerpt":"Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release that included financial information for the fiscal year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937993/000121390026036937/0001213900-26-036937-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2025"},{"label":"Net income","value":"$3.0 million for the quarter ending December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}